Prescient Therapeutics

Prescient Therapeutics (ASX: PTX), is excited to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Phase 2 clinical trial of PTX-100, the company’s first-in-class Ras pathway inhibitor. View the announcement 👉 https://hubs.ly/Q031crzc0 "The FDA’s clearance of our IND for PTX-100 is a transformative milestone for Prescient. This achievement is the culmination of tireless work from the Prescient team this year, and builds upon years of rigorous preclinical and clinical development, positioning us to unlock the therapeutic and commercial potential of PTX-100,” says CEO & MD Steven Yatomi-Clarke. #Biotech #PTX100 #CancerTherapies

Prescient Therapeutics (ASX: PTX), is pleased to announce the appointment of James McDonnell as Chief Executive Officer, effective 20 January 2025. View the announcement 👉 https://bit.ly/4gKfPp9 Mr McDonnell is an accomplished senior biopharmaceutical leader with over 25 years of experience in the global pharmaceutical industry, including significant involvement in blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML. "On behalf of the Board, I am delighted to welcome James McDonnell as the new CEO of Prescient Therapeutics. The Board conducted a thorough selection process and is confident that James's strategic vision and leadership will significantly contribute to our ambitious development plans." says Steven Engle, Non-Executive Chair. #Biotech #CancerTherapies #CellTherapies

Prescient Therapeutics (ASX: PTX) is pleased to provide the Quarterly Activities Report for the quarter ended September 2024. View the announcement 👉 https://hubs.ly/Q02WpVJd0 Highlights include: 🔵 Cash & term deposit balance of $11.5 million with spending in line with budget. 🔵 PTX-100 to focus on cutaneous T cell lymphoma (CTCL) for Phase 2 clinical trial. 🔵 Discussions with CellPryme-M parties progressing in parallel. 🔵 CellPryme data presented and well received at CAR-TCR Summit in Boston. To stay up-to-date on company news and announcements, register your details on our investor centre: https://hubs.ly/Q02WpT8q0

Pitt Street Research releases a report on Prescient Therapeutics (ASX: PTX), covering their views on why they believe PTX-100 is potentially one trial away from FDA approval, with the phase 2 trial due to start before the end of 2024. Read more 👉 https://hubs.ly/Q02NyrNp0 The research report also outlines the significant value inflection point that PTX currently sits at, having already generated a wealth of data that greatly de-risks their key asset and sets an exciting baseline of efficacy and safety. Pitt Street Research noted a valuation range of 11.6c to 16.3c per share. #Biotech #CancerTreatments #CellTherapies #PTX100

“Prescient is on the cusp of a significant value inflection with the upcoming commencement of the Phase 2 study of PTX-100, building on years of dedicated effort,” says Proactive's biotech journalist Jonathan Jackson. Read more 📣 https://hubs.ly/Q02JGNNr0 A strong financial position and the upcoming Phase 2 trial of PTX-100 were key highlights in the past quarter, focusing on refining the trial design based on feedback from T-Cell Lymphoma experts, regulatory bodies, manufacturing and commercial advisors. #Biotech #CancerTherapies #TCellTherapies

CEO Steven Yatomi-Clarke recently spoke with Sub11 Podcast host Chris Titley, where they discussed the exciting developments and plans for our primary T-cell lymphoma drug, PTX100. Listen now 👉 https://hubs.ly/Q02zBn0B0 #Biotech #CancerTherapies #PTX100

CEO Steven Yatomi-Clarke joins Jonathan Jackson from Proactive ahead of presenting the results of the PTX-100 Phase 1b study at the 15th Annual T-Cell Lymphoma Forum (TCLF) in California. Watch the interview 📣 https://hubs.ly/Q02y2Zvk0 #TCLF #PTX100 #Biotech #CancerTherapies

Prescient Therapeutics (ASX: PTX) has been invited to present our PTX-100 Phase 1b results at the 15th Annual T-Cell Lymphoma Forum (TCLF) in California next month. Read more 👉 https://hubs.ly/Q02y38_-0 The Phase 1b study of PTX-100, which targeted patients with relapsed and refractory T-cell lymphomas (r/r TCLs), has met its primary goals of demonstrating safety. It has also shown promising preliminary efficacy in r/r TCL patients, surpassing the typical results expected from standard treatments, with an overall response rate of 45%. “Prescient is committed to advancing into a Phase 2 trial in r/r TCL, with the study aiming to commence in Q3 2024. The company believes this will be a big catalyst for Prescient, potentially offering a new beacon of hope for patients with limited treatment options,” says CEO Steven Yatomi-Clarke. #Biotech #TCellTherapies #CancerTherapies #TCLF

Prescient CEO & MD Steven Yatomi-Clarke and Chief Medical Officer Dr Terry Chew were honoured to present at the 5th World Congress of Cutaneous Lymphomas in Pasadena, California last week alongside Principal investigator, Professor H. Miles Prince, AM. Meeting with key opinion leaders in the field, they presented the Phase 1b results in cutaneous T-cell lymphoma patients during a poster presentation. To stay up-to-date on Prescient’s news and announcements, register your details on our investor centre 👉 https://hubs.ly/Q02sQsg60 #Biotech #WCCL #CellTherapies

Prescient’s Principal Investigator of the PTX-100, Professor H. Miles Prince, will present results of our Phase 1b study of PTX-100 in T-cell lymphomas during a poster presentation at the 5th World Congress of Cutaneous Lymphomas in Pasadena, California. Read more 📣 https://hubs.ly/Q02sDY220 “This latest clinical response adds to the encouraging data we have previously observed in this study which includes an overall response rate of 45%. It is pleasing that our therapy continues to exhibit clinical activity and favourable safety in this patient population,” says CEO Steven Yatomi-Clarke. #Biotech #WCCL #CellTherapies